Technical Analysis for RAC - Race Oncology Ltd  

Grade Last Price % Change Price Change
B 1.310 1.55% 0.020
RAC closed up 1.55 percent on Friday, April 26, 2024, on 37 percent of normal volume. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
4 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down

Date Alert Name Type % Chg
Hammer Candlestick Bullish 0.00%
Stochastic Buy Signal Bullish 0.00%
Lizard Bullish Bullish Day Trade Setup 0.00%
Doji - Bullish? Reversal 0.00%
Strong but Oversold Other 0.00%
Wide Bands Range Expansion 0.00%
Strong, Oversold and Reversal Signs Reversal 0.00%
Oversold Stochastic Weakness 0.00%
Strong but Oversold Other 1.55%
Wide Bands Range Expansion 1.55%

   Recent Intraday Alerts

Alert Time
Fell Below Previous Day's Low 2 days ago
Down 2% 2 days ago
Down 1% 2 days ago
Up 1% 2 days ago
Gapped Up (Full) 4 days ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Race Oncology Ltd   Description

Race Oncology Limited, formerly Coronado Resources Limited, is an Australia-based specialty pharmaceutical company whose business model is to pursue and bring to market later stage assets, principally in the cancer field. The Company's Bisantrene drug is a chemotherapy drug, which is related to the anthracyclines, a class of drugs used as the first line of treatment for acute myeloid leukemia (AML) and other cancers. Its Bisantrene drug reduces cardiac toxicity compared to anthracyclines and to be effective against some cancers that have relapsed after the patients have already received high levels of anthracyclines, which makes Bisantrene as a second- or third-line treatment for patients reaching their cardio-toxic limit of anthracyclines or whose cancer has become resistant to anthracycline treatment. It has received orphan drug designation for Bisantrene in the United States. Its clinical opportunity for Bisantrene is used as a salvage treatment for elderly patients with AML.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Pharmaceutical Cancer Drugs Clinical Medicine Cancers Therapy Oncology Chemotherapy Isan Leukemia

Is RAC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 1.875
52 Week Low 0.64
Average Volume 150,677
200-Day Moving Average 1.008
50-Day Moving Average 1.212
20-Day Moving Average 1.455
10-Day Moving Average 1.375
Average True Range 0.089
RSI (14) 45.05
ADX 40.43
+DI 31.933
-DI 22.764
Chandelier Exit (Long, 3 ATRs) 1.474
Chandelier Exit (Short, 3 ATRs) 1.521
Upper Bollinger Bands 1.689
Lower Bollinger Band 1.221
Percent B (%b) 0.19
BandWidth 32.137
MACD Line 0.009
MACD Signal Line 0.055
MACD Histogram -0.0463
Fundamentals Value
Market Cap 167.89 Million
Num Shares 128 Million
EPS -0.05
Price-to-Earnings (P/E) Ratio -28.48
Price-to-Sales 0.00
Price-to-Book 48.43
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.393
Resistance 3 (R3) 1.383 1.347 1.379
Resistance 2 (R2) 1.347 1.326 1.351 1.374
Resistance 1 (R1) 1.328 1.313 1.338 1.338 1.370
Pivot Point 1.292 1.292 1.296 1.296 1.292
Support 1 (S1) 1.273 1.271 1.283 1.283 1.250
Support 2 (S2) 1.237 1.258 1.241 1.246
Support 3 (S3) 1.218 1.237 1.241
Support 4 (S4) 1.228